The S&P 500 has grown notably top-heavy. The 10 largest companies currently make up about 40% of its value, compared to 20% to 25% for the most of the period since 1980, while technology accounts for nearly 40% of the standard index but only roughly 16% of the equal-weight version. That focus paid off while AI spending boosted the biggest names. That said, things have started to become costly.
On November 19, the S&P 500 dropped 2.02% to 7,175.83, the Nasdaq Composite sank 2.25% to 23,879.20, and the Dow closed below 50,000. Anthropic’s IPO failed to revive the AI trade, and the S&P 500 fell further below its 200-day moving average. Readers interested in the stocks hardest impacted by the latest sequence of tech selloffs can see more in our list of oversold AI stocks that continue to draw analyst interest, and those who want to stay in the buildout can read more about these AI infrastructure stocks to buy for the long-term.
Calls to spread risk have getting been louder across the market. Dryden Pence, chief investment officer at Pence Capital, favors an equal-weight S&P 500 as a core holding because ten stocks make up roughly 40% of the S&P 500 and 50% of the Nasdaq. Moreover, according to Credo’s Benjamin Newton, equal weight increases exposure to industrials, financials, and healthcare. Earnings support the case. Russell Investments said analysts expected third-quarter earnings growth of 20.3% for the Magnificent Seven and 27.7% for the rest of the 493 S&P 500 companies.
The case for looking beyond mega-cap technology is that major tech companies have kept expanding. Their valuations already account for a significant amount of the projected AI-driven earnings acceleration, while an array of healthcare, industrial, consumer, finance, and energy companies are expanding at rates that might surprise investors.
With that in mind, let’s take a look at the 10 best high-growth stocks to diversify away from Big Tech. The stocks below are distinct from our previous coverage of high-growth stocks outside Big Tech, which screened for non-tech companies with a 5-year EPS growth of at least 25%. Readers who want more ideas beyond the mega-caps can make use of both lists.

Our Methodology
For this list, we screened for non-tech stocks that boast a 3-year revenue growth rate of at least 30%. We have also mentioned hedge fund ownership numbers for Q3 2026 to provide insight into smart money sentiments around each stock.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. argenx SE (NASDAQ:ARGX)
Revenue Growth Over the Past 3 Years: 116.47%
Number of Hedge Fund Holders: 42
Argenx SE is a global biotechnology company developing antibody-based therapies for the treatment of severe autoimmune and rare diseases. The company raked in $1.7 billion in global product net sales, up 54% year-over-year and 13% quarter-over-quarter. Moreover, VYVGART net sales reached $1.7 billion for the quarter and $4.5 billion for the first nine months of 2026, compared to $1.1 billion and $2.9 billion in the same periods in 2025.
Argenx also reported total revenue of $1.75 billion in the third quarter, which exceeded consensus forecasts, while operating profit of $486 million fell short of some analyst expectations. However, the company expects approximately $4 billion in combined R&D and selling, general, and administrative spending in 2026, a 45% increase over 2025. The expense supports an expanded pipeline and the possibility of up to five US launches in 2027, though it also raises the bar for execution.
The Phase 3 ALKIVIA trial provided a crucial proof point. VYVGART Hytrulo had a 15.4-point mean advantage over placebo on the Total Improvement Score at Week 52, with a p-value of 0.0011, while the immune-mediated necrotizing myopathy subgroup had a 14.8-point difference and a p-value of 0.0048. However, the dermatomyositis subgroup demonstrated a 14.5-point numerical advantage that didn’t reach statistical significance. Our review of Argenx’s Phase 3 myositis trial asks whether that miss limits commercial opportunities.
9. Permian Resources Corporation (NYSE:PR)
Revenue Growth Over the Past 3 Years: 33.45%
Number of Hedge Fund Holders: 49
Permian Resources is a pure-play Permian Basin operator. The company announced solid third-quarter earnings, with oil and gas sales jumping 48% year-over-year to $1.96 billion. Oil production averaged 208,000 barrels per day, up roughly 10,000 barrels per day from the second quarter, with total output reaching 458,000 barrels of oil equivalent per day. Despite lower oil prices compared to the previous quarter, the company generated a record adjusted free cash flow of $846 million, or $0.98 per share. It also cut controllable cash expenses to a record low of $7.05 per barrel of oil equivalent, while lifting the midpoint of its 2026 oil production projection to about 202,000 barrels per day, around 11% more than last year.
The main risk remains crude oil price volatility, though regional natural gas constraints ought to be addressed as well. Since oil accounts for around 84% of Permian Resources’ revenue, a prolonged drop in crude prices poses the biggest threat to the company’s free cash flow, despite its industry-low cost structure. Our analysis of Permian Resources explores whether record free cash flow can be sustained in the face of commodity price volatility and gas market pressure. Read about it here.
8. Ascendis Pharma A/S (NASDAQ:ASND)
Revenue Growth Over the Past 3 Years: 147.23%
Number of Hedge Fund Holders: 49
Ascendis Pharma reported robust third-quarter earnings, with total product revenue up 89% year-over-year to €366 million. Total revenue rose to €370 million from €214 million in the third quarter of 2025. The growth was broad-based across the company’s three marketed goods. YORVIPATH generated €291 million in product revenue, while SKYTROFA added €59 million and the newly launched YUVIWEL contributed €16 million.
The company is also improving its financial position. Third-quarter operating cash flow came in at €189 million, and Ascendis revised its full-year 2026 operating cash flow projection to at least €600 million. This cash generation supports the previously authorized $400 million share buyback and gives the company more room to fund development plans.
Management aims to generate more than €5 billion in annual product revenue by 2030 and €10 billion by 2035, aided by its existing products, potential label expansions, and new medicines created with TransCon technology. In addition, the company expects 15 more YORVIPATH markets in 2027, as well as the first European YUVIWEL launch in Germany, pending approval.
The opportunity is substantial, but execution is crucial since the company hasn’t released detailed 2027 financial forecasts yet, and investors will be looking to see if new launches and margin expansion can maintain recent growth. The concern is whether Ascendis’ proprietary platform can support the company’s next growth phase.
7. DraftKings Inc. (NASDAQ:DKNG)
Revenue Growth Over the Past 3 Years: 39.29%
Number of Hedge Fund Holders: 51
The gambling giant reported third-quarter revenue of $1.329 billion, up 16% year-over-year from $1.144 billion. The rise was led by increased customer engagement and a stronger Sportsbook net revenue margin, with monthly unique payers up 13% and sports consumer volume up 22%. The profitability picture was less bright. The company recorded a net loss of $468.7 million, higher than the $256.8 million loss a year before, while adjusted EBITDA was negative $316.9 million, compared to a loss of $126.5 million in the prior-year quarter. The decrease was mostly caused by increased investment in Predictions, DraftKings’ prediction-markets division.
That said, the legal situation has improved. Earlier this year, the Ninth Circuit Court of Appeals concluded that sports-related prediction-market contracts were not “swaps” under federal commodities law, allowing Nevada to apply its gaming restrictions and refusing Kalshi, Crypto.com, and Robinhood’s injunction requests. DraftKings stock jumped as much to 10% following the news. For DraftKings, the challenge is to translate a more favorable regulatory environment into earnings growth. Our coverage examines whether the prediction-market ruling provides DraftKings a long-term competitive advantage.
6. TKO Group Holdings, Inc. (NYSE:TKO)
Revenue Growth Over the Past 3 Years: 60.74%
Number of Hedge Fund Holders: 58
TKO Group is a sports and entertainment conglomerate that owns UFC, WWE, and other live-event and media enterprises. The company reported third-quarter revenue of $1.360 billion, a 21% increase year-over-year, while adjusted EBITDA rose 54% to $555.7 million. Net income climbed to $277.9 million from $106.8 million a year ago, while the adjusted EBITDA margin improved to 41% from 32%. For the second straight quarter, management boosted its full-year 2026 guidance. The company is now projecting revenue of $5.79 billion to $5.83 billion and adjusted EBITDA of $2.295 billion to $2.315 billion, up $10 million and $15 million at the midpoint, respectively, from its August forecast.
TKO has also returned over $1.6 billion to equity holders year-to-date through share buybacks and dividends. That capital return, together with improved profitability, shows the company’s ability to transform demand for live sports and entertainment into cash generation. What matters is if TKO can maintain its momentum as it increases events, media partnerships, and commercial potential. Cooper Investors believes the company is benefiting for now, calling it the company the ‘anchor’ of its Compounding Capital pool.
5. Coinbase Global, Inc. (NASDAQ:COIN)
Revenue Growth Over the Past 3 Years: 31.00%
Number of Hedge Fund Holders: 63
Coinbase is attempting to quit being a bet on crypto trading volume. The company’s subscription and service revenue accounted for 49% of net revenue in the third quarter. Prediction markets generated over $200 million in annualized revenue, with traders up 60% from the previous quarter, and prediction markets and derivatives combined accounted for over 25% of transaction revenue.
Nonetheless, the trading business remains slow. Revenue of $1.216 billion proved unchanged sequentially and 35% lower than a year ago, while transaction revenue dropped by 44% to $590 million. Moreover, net income of $718.7 million came after lower operating costs and gains from cryptocurrency investments, and the stock declined more than 5% after hours. Our research of Coinbase’s institutional pivot examines whether institutions can offset decreased retail trading.
4. Interactive Brokers Group, Inc. (NASDAQ:IBKR)
Revenue Growth Over the Past 3 Years: 35.57%
Number of Hedge Fund Holders: 75
Interactive Brokers keeps adding clients faster than markets increase volatility. Customer accounts climbed 35% to 5.58 million, customer equity by 27% to $964.7 billion, and customer margin loans by 36% to $105.2 billion. The pretax margin came in at 78%, marking the eighth straight quarter above 70%.
That said, Q3 results were mixed, with revenue higher than expected and earnings falling short. Net revenue increased to $1.91 billion, with net interest income growing 19% to $1.15 billion and commission revenue up 12% to $602 million. Adjusted earnings per share of $0.67 missed expectations, capping a run of five consecutive beats. DARTs came in at 11% below the second quarter, indicating a slower trading volume. Meanwhile, the company boosted its quarterly dividend by 71%, to $0.15 from $0.0875.
October showed the same split. DARTs were 4% lower than a year before, client equity fell 4% to $928.6 billion in September, and accounts increased 34% to 5.678 million. Whether the share premium to five-year valuation is justified is the question in our analysis of Interactive Brokers. Read about it here.
3. Robinhood Markets, Inc. (NASDAQ:HOOD)
Revenue Growth Over the Past 3 Years: 48.27%
Number of Hedge Fund Holders: 90
Prediction markets are now a legitimate revenue stream for Robinhood. Event contracts generated $173 million in the third quarter, up from $156 million in the second, with a record 16.4 billion contracts traded. Robinhood now has 14 business lines with at least $100 million in annualized revenue, and Gold subscribers increased 34% to a record 5.2 million.
While the quarter achieved a revenue record, it failed to meet earnings expectations. Revenue increased to $1.42 billion, with EPS of $0.51 versus $0.55 projected, while crypto revenue of $120 million fell 55% from a year ago. October net deposits surpassed $13 billion month to date, including $6 billion from the Dell family’s contribution to Trump Accounts.
The stock has not kept pace with the business. Prior to the announcement, shares closed near $94.61, down about 18% for the year and 37% below their 52-week high. Robinhood is leaning further into event contracts, and its expanded prediction markets collaboration with Crypto.com gives the product a broader distribution network.
2. Nu Holdings Ltd. (NYSE:NU)
Revenue Growth Over the Past 3 Years: 48.27%
Number of Hedge Fund Holders: 90
Nu is expanding on three fronts simultaneously. Nu Mexico began operations as a full bank on August 6, and customer deposit insurance coverage increased 16-fold. Overall, Mexico added 870 thousand consumers to reach 16.6 million, Colombia reached 6.1 million, and Nu US launched on September 10 and reached customers in all 50 states.
The results support the story. Net income reached a record $1.1 billion, up 31% on an FX-neutral basis, with a 32% return on equity, while gross revenue increased 37% to $6.3 billion. The efficiency ratio improved to 19.3%, and deposits grew by 19% to $47.5 billion.
Analysts also remained positive. Needham’s Kyle Peterson reiterated a Buy rating and a $19 price target, saying the results alleviated near-term concerns about Brazil’s macroeconomic outlook. The stock was still down more than 29% for the year before to the report, which helps explain the scale of the rebound, and our coverage of Nu’s double-digit rally digs into what drove it.
1. Eli Lilly and Company (NYSE:LLY)
Revenue Growth Over the Past 3 Years: 31.69%
Number of Hedge Fund Holders: 137
Eli Lilly is the Indianapolis-based company behind the the GLP-1 drugs Mounjaro and Zepbound. Tirzepatide, the active component in both, is the engine. Mounjaro’s revenue increased by 65% to $10.7 billion, while Zepbound’s jumped by 49% to $5.35 billion. The new oral GLP-1 Foundayo raised $184 million, up from $98 million the previous quarter, while Kisunla for Alzheimer’s increased 175% to $193 million. A head-to-head Phase 3 trial of retatrutide against Ozempic in type 2 diabetes was likewise positive.
Eli Lilly raised its outlook sharply. Revenue rose 39% to $24.4 billion in the third quarter, while adjusted EPS of $7.48 exceeded expectations for the fifth time in a row. The company’s full-year revenue projection climbed to $91 billion to $92 billion from $85 billion to $87 billion, and the stock gained approximately 4% pre-market. Revenue included one-time Jardiance milestones, with no more remaining.
However, pricing is the offset. Realized prices in the US declined 7%, while prices outside the States fell by 29%. Whether the momentum can outlast the sector rotation is the question in our look at how the rotation weighed on Lilly in the third quarter.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years





